This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Relton, J. K. Articles by Yenari, M. A. Search for Related Content PubMed PubMed Citation Articles by Relton, J. K. Articles by Yenari, M. A. Related Collections Animal models of human disease Acute Cerebral Infarction Other Stroke Treatment - Medical Other Vascular biology

(Stroke. 2001;32:199.)
© 2001 American Heart Association, Inc.

Original Contributions

Inhibition of 4 Integrin Protects Against Transient Focal Cerebral Ischemia in Normotensive and Hypertensive Rats

Jane K. Relton, PhD; Kevin E. Sloan, MS; Erica M. Frew, BS; Eric T. Whalley, PhD; Steven P. Adams, PhD Roy R. Lobb, DPhil

From Biogen Inc, Cambridge, Mass.

Correspondence to Jane Relton, PhD, Biogen, Inc, 14 Cambridge Center, Cambridge, MA 02142. E-mail Jane_Relton{at}Biogen.com

Background and Purpose—The present study was performed to determine the role of 4 (CD49d), a member of the integrin family of adhesion molecules, in ischemic brain pathology.

Methods—Male spontaneously hypertensive rats (SHR) or Sprague-Dawley rats underwent 60-minute middle cerebral artery occlusion (MCAO) followed by 23-hour reperfusion. Animals were injected intravenously with 2.5 mg/kg anti-rat 4 antibody (TA-2) or isotype control antibody (anti-human LFA-3 IgG₁, 1E6) 24 hours before MCAO. Infarct volume was quantified by staining of fresh tissue with tetrazolium chloride and myeloperoxidase activity measured in SHR tissue homogenates 24 hours after MCAO. In SHR, mean arterial blood pressure was recorded before and after MCAO in animals treated with TA-2 and 1E6. Fluorescence-activated cell sorting analysis was performed on peripheral blood leukocytes before and after MCAO.

Results—TA-2 treatment significantly reduced total infarct volume by 57.7% in normotensive rats (1E6, 84.2±11.5 mm³, n=17; TA-2, 35.7±5.9 mm³, n=16) and 35.5% in hypertensive rats (1E6, 146.6±15.5 mm³, n=15; TA-2, 94.4±25.8 mm³, n=11). In both strains, TA-2 treatment significantly reduced body weight loss and attenuated the hyperthermic response to MCAO. In SHR, treatment with TA-2 significantly reduced brain myeloperoxidase activity. Resting mean arterial blood pressure was unaffected by treatment. Leukocyte counts were elevated in TA-2–treated rats. Fluorescence-activated cell sorting analysis demonstrated the ability of TA-2 to bind to CD3+, CD4+, CD8+, and CD11b+ cells in both naive animals and after MCAO.

Conclusions—These data demonstrate that inhibition of 4 integrin can protect the brain against ischemic brain injury and implicate endogenous 4 integrin in the pathogenesis of acute brain injury. The mechanism by which 4 integrin inhibition offers cerebroprotection is independent of blood pressure modulation and is likely due to inhibition of leukocyte function.

Editorial Comment

Midori A. Yenari, MD, Guest Editor

Departments of Neurosurgery and Neurology Stanford University School of Medicine Stanford, California

This article has been cited by other articles:

				J. M. Gee, A. Kalil, C. Shea, and K. J. Becker Lymphocytes: Potential Mediators of Postischemic Injury and Neuroprotection Stroke, February 1, 2007; 38(2): 783 - 788. [Abstract] [Full Text] [PDF]

				Y. Chen, C. Ruetzler, S. Pandipati, M. Spatz, R. M. McCarron, K. Becker, and J. M. Hallenbeck Mucosal tolerance to E-selectin provides cell-mediated protection against ischemic brain injury PNAS, December 9, 2003; 100(25): 15107 - 15112. [Abstract] [Full Text] [PDF]

				J. G. T. VI, D. C. Tang, S. A. Savage, S. F. Leitman, S. I. Heller, G. R. Serjeant, G. P. Rodgers, and S. J. Chanock Variants in the VCAM1 gene and risk for symptomatic stroke in sickle cell disease Blood, December 15, 2002; 100(13): 4303 - 4309. [Abstract] [Full Text] [PDF]

				C.J.M. Frijns and L.J. Kappelle Inflammatory Cell Adhesion Molecules in Ischemic Cerebrovascular Disease Stroke, August 1, 2002; 33(8): 2115 - 2122. [Abstract] [Full Text] [PDF]

				J. Bao, K. Sato, M. Li, Y. Gao, R. Abid, W. Aird, M. Simons, and M. J. Post PR-39 and PR-11 peptides inhibit ischemia-reperfusion injury by blocking proteasome-mediated Ikappa Balpha degradation Am J Physiol Heart Circ Physiol, December 1, 2001; 281(6): H2612 - H2618. [Abstract] [Full Text] [PDF]

				K. Yanaka, N. Kato, T. Nose, K. J. Becker, J. M. Harlan, and R. K. Winn Does Antibody to the {alpha}4 Integrin Inhibit the Function of Lymphocytes and Monocytes? Response Stroke, August 1, 2001; 32(8): 1932 - 1933. [Full Text] [PDF]

				K. Becker, D. Kindrick, J. Relton, J. Harlan, R. Winn, and M. A. Yenari Antibody to the {{alpha}}4 Integrin Decreases Infarct Size in Transient Focal Cerebral Ischemia in Rats Editorial Comment Stroke, January 1, 2001; 32(1): 206 - 211. [Abstract] [Full Text] [PDF]